Tatiane B Ribeiro

Tatiane B Ribeiro


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 April 2023 in Journal of Clinical Epidemiology
Verified
Journal Article
Closed access
TRTatiane B Ribeiro
Tatiane B Ribeiro
CBCharles L. Bennett
Charles L. Bennett
LCLuis Enrique Colunga-Lozano
Luis Enrique Colunga-Lozano
AAAna Paula Vieira Araujo
Ana Paula Vieira Araujo
IHIztok Hozo
Iztok Hozo
BDBenjamin Djulbegovic
Benjamin Djulbegovic

28 November 2019 in International Journal of Technology Assessment in Health Care
Verified
Journal Article
Closed access
PDF file
TRTatiane B Ribeiro
Tatiane B Ribeiro
ARAdalton Ribeiro
Adalton Ribeiro
LRLuíza de Oliveira Rodrigues
Luíza de Oliveira Rodrigues
GHGuilherme Harada
Guilherme Harada
MNMoacyr Roberto Cuce Nobre
Moacyr Roberto Cuce Nobre
ObjectiveThis paper aims to describe the clinical and regulatory aspects of new drugs and indications that were approved for lung, breast, prostate, and colorectal cancer, from 2016 to 2018, in order to provide health technology assessment trends in oncology.MethodsData were collected from the US Food and Drug Administration (FDA) online database for new medications and indications approved for the above-mentioned types of cancer. Data regarding clinical study characteristics and regulatory information were collected.ResultsFrom 2016 to 2018, 53 percent of the FDA approvals of new drugs and indications for the most incident cancers were for oral protein kinase inhibitor monotherapy for advanced lung cancer. Since 2018, four drugs were approved as tumor-agnostic therapies. A biomarker was included in 72 percent of indications, and 58 percent of approvals were for targeted therapies, potentially heralding an end to research into conventional cytotoxic agents. A special designation for faster approval was granted in 78 percent of new approvals. The majority of the studies were open label randomized controlled trials (RCTs) (44 percent), followed by blind RCTs, single-arm clinical trials, and cohort studies. Only 14 percent of studies used overall survival as the primary end point; the vast majority used surrogate end points, and did not use patient-important outcomes. Three biosimilars were approved in the period.ConclusionAdvanced lung cancer therapy, mainly targeted drugs, accounted for 53 percent of approvals. Special designations for faster approval were used in 78 percent of FDA approvals, and four drugs were approved for tumor-agnostic treatment—a new form of approval.

31 January 2022 in Journal of Clinical Epidemiology
Verified
Journal Article
Closed access
TRTatiane B Ribeiro
Tatiane B Ribeiro
LCLuis Enrique Colunga-Lozano
Luis Enrique Colunga-Lozano
AAAna Paula Vieira Araujo
Ana Paula Vieira Araujo
CBCharles Lee Bennett
Charles Lee Bennett
IHIztok Hozo
Iztok Hozo
BDBenjamin Djulbegovic
Benjamin Djulbegovic

24 July 2020 in PLOS ONE
Verified
Journal Article
Open access
PDF file
TRTatiane B Ribeiro
Tatiane B Ribeiro
LBLewis Buss
Lewis Buss
CWCole Wayant
Cole Wayant
MNMoacyr Roberto Cuce Nobre
Moacyr Roberto Cuce Nobre
Regulatory agencies around the world have been using flexible requirements for approval of new drugs, especially for cancer drugs. The US Food and Drug Administration (FDA) is mostly the first agency to approve new drugs worldwide, mainly due to the faster terms of the accelerated pathway and breakthrough therapy designation. Surrogate endpoints and preliminary data (e.g. single-arm and phase 2 studies) are used for these new approvals, however larger effect sizes are expected. We aim to compare FDA Accelerated vs Regular Pathway approvals and Breakthrough therapy designations (BTD) for lung cancer treatments between 2006 and 2018 regarding study design, sample size, outcome measures and effect size. We assessed the FDA database to collect data from studies that formed the basis of approvals of new drugs or indications for lung cancer spanning from 2006 to 2018. We found that accelerated pathway approvals are based on significantly more single-arm studies with small sample sizes and surrogate primary endpoints. However, effect size was not different between the pathways. A large proportion of studies used to support regular pathway approvals also showed these characteristics that are related to low quality and uncertain evidence. Compared to other approvals, BTD were more frequently based on single-arm studies. There was no significant difference in use of surrogate endpoints or sample size. 44% of BTD were based on studies demonstrating large effect sizes, proportionally more than approvals not receiving this designation. In conclusion, based on the indicators of evidence quality we extracted, criteria’s for granting accelerated approval and breakthrough therapy designation seen not clear. Faster approvals are in the majority full of uncertainties which should be viewed with caution and the patient have to be communicated to allow shared decision making. Post-marketing validation is essential.

1 March 2021 in Current Diabetes Reviews
Verified
Journal Article
Closed access
PDF file
RCRenata Cunha Carvalho
Renata Cunha Carvalho
FNFernanda Ayache Nishi
Fernanda Ayache Nishi
TRTatiane B Ribeiro
Tatiane B Ribeiro
GFGustavo Galvão França
Gustavo Galvão França
PAPatricia Melo Aguiar
Patricia Melo Aguiar
Background: Many people are still getting affected by uncontrolled glycemic events during hospital admission, which encompasses hypoglycemia, hyperglycemia, and high glycemic variability. Introduction: Primary studies have shown an association of glycemic dysregulation with increased length of hospital stay and mortality among overall patients, however, there is no systematic review of current evidence on the association between uncontrolled in-hospital glycemia in patients with diabetes and health outcomes. This study aimed to systematically review the current evidence on the association between uncontrolled in-hospital glycemia in patients with diabetes and health outcomes. Methods: The association between glycemic dysregulation and health outcomes for inpatients with diabetes was systematically reviewed. PubMed, Embase, and LILACS databases were searched. Two independent reviewers were involved in each of the following steps: screening titles, abstracts, and fulltexts; assessing the methodological quality; and extracting data from included reviews. Descriptive analysis method was used. Results: Seven cohort studies were included, and only two had a prospective design, consisting of 7,174 hospitalized patients with diabetes. In-hospital occurrence of hypoglycemia, hyperglycemia, and glycemic variability were assessed, and outcomes were mortality, infections, renal complications, and adverse events. Among the exposure and outcomes, an association was observed between severe hypoglycemia and mortality, hyperglycemia and infection, and hyperglycemia and adverse events. Conclusion: In-hospital uncontrolled glycemia in patients with diabetes is associated with poor health outcomes. More studies should be conducted for proper investigation because diabetes is a complex condition. Effects of glycemic dysregulation should be investigated on the basis of overall health of a patient instead from only organ-target perspective, which makes the investigation difficult.

7 June 2018 in Brazilian Journal of Pharmaceutical Sciences
Verified
Journal Article
Open access
PDF file
TRTatiane B Ribeiro
Tatiane B Ribeiro
DMDaniela Oliveira de Melo
Daniela Oliveira de Melo
FMFlávia de Oliveira Motta Maia
Flávia de Oliveira Motta Maia
EREliane Ribeiro
Eliane Ribeiro
Falls are the second leading cause of accidental and unintentional injury deaths worldwide. Inpatient falls in hospital settings are likely to prolong the length of stay of patients in nearly 6.3 days, leading to increased hospitalization costs. The causes of fall incidents in healthcare facilities are multifactorial in nature and certain medications use could be associated with these incidents. This review seeks to critically evaluate the available literature regarding the relationship between inpatient falls and medication use. A comprehensive search was performed on MEDLINE, EMBASE and Lilacs with no time restriction. The search was filtered using English, Spanish or Portuguese languages. Our study evaluated medication use and inpatients falls that effectively happen, considering all ages and populations. An assessment of bias and quality of the studies was carried out using an adapted tool from the literature. The drugs were classified according to the Anatomic Therapeutics Chemical Code. The search strategy retrieved 563 records, among which 23 met the eligibility criteria; ninety three different pharmacological subgroups were associated with fall incidents. Our critical review suggests that the use of central nervous system drugs (including anxiolytics; hypnotics and sedatives; antipsychotics; opioids; antiepileptics and antidepressants) has a greater likelihood of causing inpatient falls. A weak relationship was found between other pharmacological subgroups, such as diuretics, cardiovascular system-related medications, and inpatient fall. Remarkably, several problems of quality were encountered with regard to the eligible studies. Among such quality problems included retrospective design, the grouping of more than one medication in the same statistical analysis, limited external validity, problems related to medication classifications and description of potential confounders.